Panmure Gordon reiterated their buy rating on shares of Midatech Pharma PLC (LON:MTPH) in a research note released on Friday morning. Panmure Gordon currently has a GBX 380 ($4.96) target price on the stock.
Midatech Pharma PLC (LON:MTPH) opened at 130.00 on Friday. Midatech Pharma PLC has a 1-year low of GBX 100.51 and a 1-year high of GBX 285.00. The firm has a 50-day moving average price of GBX 144.86 and a 200-day moving average price of GBX 140.82. The company’s market capitalization is GBX 43.60 million.
About Midatech Pharma PLC
Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company’s segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms.
Receive News & Ratings for Midatech Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.